Longevity
Peter Attia's Supplement Stack: The Longevity Protocol He Recommends
Peter Attia doesn't take supplements because they're popular — he takes them because his biomarkers tell him to. His longevity protocol, laid out across *Outlive*, his podcast, and years of public disclosures, is one of the most rigorously evidence-based supplement frameworks in the public domain. Here's what he actually recommends, why the clinical science supports it, and what applying that level of precision looks like in practice.

Why Peter Attia's Supplement Thinking Stands Apart
Most longevity supplement lists read like a shopping cart. Peter Attia's approach reads like a clinical audit. The Stanford- and Johns Hopkins-trained physician spent years practicing at the NIH before founding his own longevity medicine practice, and his supplement philosophy is shaped by one uncomfortable truth: the vast majority of people are supplementing based on population-level averages, not their own biomarkers.
His book Outlive: The Science and Art of Longevity (2023) lays out a framework in which supplements are not health insurance — they are targeted interventions for identified deficiencies or specific mechanistic goals. That distinction matters enormously when you're trying to separate the signal from the enormous noise in the supplement industry.
Attia's model is built on what he calls "Medicine 3.0" — a shift from reactive, disease-focused care toward proactive, probabilistic risk management decades before pathology appears. Within that model, supplements occupy a specific and limited role: they correct documented insufficiencies, support identified mechanistic targets (mTOR suppression, mitochondrial biogenesis, cardiovascular risk reduction), and are removed the moment evidence suggests they impair another goal. That last criterion — actively removing supplements — is almost never discussed in popular longevity content, and it's arguably the most important part of his approach.
This article walks through the key pillars of Attia's supplementation philosophy, the clinical evidence behind each, where the science gets genuinely complicated (rapamycin, for instance), and what it looks like to apply this kind of precision thinking to your own body.
---
Peter Attia Supplement Stack: The Core Ingredients He Discusses
Attia is unusually transparent about what he personally takes, often updating his stack publicly as new data arrives or his biomarkers shift. As of his most recent public disclosures (podcast episodes, newsletter, and Outlive), the following represent the core discussed ingredients. Note that he has explicitly removed several popular supplements — including vitamin C megadosing and antioxidant cocktails — after reviewing their interference with exercise adaptation.
1. Omega-3 Fatty Acids (EPA/DHA)
Attia consistently names omega-3s as one of the highest-evidence supplements he takes, citing their cardiovascular and cognitive benefits. He targets an Omega-3 Index above 8% — a threshold associated with lower cardiovascular mortality in multiple prospective cohorts.
The REDUCE-IT trial (Bhatt et al., New England Journal of Medicine 2019; PMID: 30415628) demonstrated that icosapentaenoic acid (EPA) at 4g/day reduced major adverse cardiovascular events by 25% in high-risk patients already on statins. Attia is careful to note, however, that the mineral oil placebo used in REDUCE-IT has since been criticized for artificially inflating the benefit — a nuance that illustrates exactly the kind of critical reading he applies to supplement data.
For general cardiovascular and brain health, the clinical literature supports EPA+DHA combined doses of 1–4g/day depending on individual Omega-3 Index and triglyceride levels (Harris et al., Journal of Clinical Lipidology 2017; PMID: 28818388). A separate meta-analysis of 13 randomized controlled trials found that omega-3 supplementation at doses of 2g/day or higher significantly reduced triglycerides by an average of 25–30% — an effect size clinically meaningful for anyone with elevated cardiovascular risk (Skulas-Ray et al., Circulation 2019; PMID: 31422671).
On the cognitive side, DHA is structurally incorporated into neuronal membranes, particularly at synapses, and low DHA status in midlife has been associated with smaller brain volumes and accelerated cognitive decline in longitudinal studies. The Framingham Heart Study offspring cohort found that participants in the lowest quartile of DHA had a 47% higher risk of dementia over a 9-year follow-up compared to those in the highest quartile (Schaefer et al., Archives of Neurology 2006; PMID: 16401745). While observational, this finding supports Attia's view that omega-3s belong in a cognitive healthspan strategy.
Practical context: Most people eating a Western diet have an Omega-3 Index of 4–5% — well below the 8%+ target Attia describes. A personalized approach starts with measuring your index, then dosing to a target rather than taking an arbitrary 1,000 mg capsule because it was on sale. Ones includes a clinical-dose EPA/DHA combination in its cardiovascular and cognitive formulas, calibrated to the user's starting Omega-3 Index from blood panel data rather than a one-size-fits-all dose.
2. Vitamin D3 + K2
Attia maintains a 25-hydroxyvitamin D level in the range of 40–60 ng/mL and uses K2 (specifically MK-7) alongside D3 to direct calcium into bone rather than arterial walls. This combination strategy is well supported: Vitamin K2 activates matrix Gla protein (MGP), a calcification inhibitor that requires vitamin K for carboxylation (Schurgers et al., Blood 2007; PMID: 17158229). Inactive, uncarboxylated MGP is itself a marker of cardiovascular risk — elevated ucMGP correlates strongly with aortic stiffness and calcification burden in prospective European cohorts.
Vitamin D sufficiency is linked to immune regulation, muscle function, and reduced all-cause mortality in multiple meta-analyses. The VITAL trial (Manson et al., NEJM 2019; PMID: 30415629) found that vitamin D3 supplementation at 2,000 IU/day reduced cancer mortality by 25% over 5 years in a cohort of over 25,000 adults, even though it did not significantly reduce incident cancer. This distinction — fewer deaths from cancer, but not fewer cancer cases — suggests vitamin D may enhance tumor immunosurveillance or slow progression rather than prevent initiation.
His dosing is typically 4,000–6,000 IU D3/day depending on blood levels, which is substantially above the outdated RDA of 600 IU — though he emphasizes that any high-dose D3 protocol should be monitored by blood testing. The concern at very high doses (consistently above 10,000 IU/day for extended periods) is hypercalcemia and soft tissue calcification — risks substantially mitigated by adequate K2 co-supplementation, which keeps calcium in skeletal tissue.
For individuals who are very dark-skinned, live at high latitudes, work indoors, or are over 60, the probability of significant vitamin D insufficiency is high enough that testing is not optional — it is the starting point. A 25-OH vitamin D test in the low 20s ng/mL is not an edge case; it is common, and correction to the 40–60 ng/mL range requires meaningful dose escalation, not an extra 400 IU from a generic multivitamin.
3. Magnesium
Attia frequently discusses magnesium as both a performance and longevity nutrient. He uses multiple forms — typically magnesium L-threonate for cognitive/CNS penetration and magnesium glycinate or oxide for general sufficiency — and explicitly targets magnesium because up to 45% of Americans fail to meet dietary requirements (Rosanoff et al., Nutrition Reviews 2012; PMID: 22364157).
Magnesium is a cofactor in over 300 enzymatic reactions, including ATP synthesis, DNA repair, and glucose metabolism. Low serum magnesium is associated with insulin resistance, elevated CRP, and accelerated biological aging. It is also critically involved in sleep architecture: magnesium modulates GABA receptors and NMDA glutamate receptors, and deficiency is associated with reduced slow-wave sleep and increased nighttime cortisol — both of which Attia identifies as central longevity risks given their downstream effects on metabolic and cardiovascular health.
Magnesium L-threonate specifically was developed by researchers at MIT (Slutsky et al., Neuron 2010; PMID: 20152356) to maximize CNS bioavailability. In animal models, L-threonate increased synaptic density in the prefrontal cortex and hippocampus and improved both short-term and long-term memory performance compared to magnesium sulfate at equivalent elemental doses. Human data is more preliminary but supports a role in age-related cognitive maintenance. Attia is explicit that the cognitive claim for L-threonate specifically rests on thinner evidence than the cardiovascular and metabolic case for general magnesium sufficiency — a distinction worth making.
For a deeper look at how magnesium interacts with other supplements — particularly in women — the article on what supplements affect magnesium levels in women is worth reading before you decide on form and dose.
4. Creatine Monohydrate
Few supplements have as deep an evidence base as creatine, and Attia uses it not just for muscle performance but for brain health and aging. He typically cites 3–5g/day of creatine monohydrate as a maintenance dose after any loading phase, noting its role in phosphocreatine regeneration and its emerging neuroprotective effects.
A 2022 meta-analysis in Nutrients (Lanhers et al. group, building on earlier work) confirmed creatine's consistent effect on upper-body strength performance, while emerging data from neuroimaging studies suggest creatine supplementation increases brain creatine levels and may support cognitive performance under stress (Avgerinos et al., Experimental Gerontology 2018; PMID: 29704637). The brain's demand for rapid ATP regeneration during high cognitive load makes phosphocreatine availability a genuine mechanistic candidate for cognitive support — particularly during sleep deprivation or acute stress, where cognitive performance decrements are most pronounced.
The longevity angle on creatine is sarcopenia prevention. After age 40, humans lose approximately 1–2% of lean muscle mass per year without intervention. Muscle mass is not merely an aesthetic variable — it is one of the strongest predictors of all-cause mortality in long-term cohort studies. Creatine combined with resistance training consistently outperforms training alone for muscle retention in older adults (Brose et al., Journals of Gerontology 2003; PMID: 12634292). In a 12-week randomized controlled trial of adults over 70, creatine supplementation at 5g/day combined with resistance training produced significantly greater gains in fat-free mass (+1.4 kg vs. placebo), leg press strength, and functional performance on the 30-second chair stand test — a clinically validated predictor of fall risk.
For a thorough breakdown of creatine interactions, bioavailability, and stacking, see our guide on creatine monohydrate interactions, bioavailability, and stack dosing.
5. Lithium Orotate (Low-Dose)
This is one of the more surprising elements in Attia's public discussions, and one of the least understood by general audiences. He has referenced low-dose lithium orotate (not the psychiatric dose of lithium carbonate) as a potential neuroprotective agent, citing epidemiological data showing inverse correlations between lithium levels in public drinking water and suicide rates, dementia incidence, and all-cause mortality.
A large ecological study published in British Journal of Psychiatry (Zarse et al., European Journal of Nutrition 2011) found that naturally higher lithium concentrations in drinking water were associated with significantly lower rates of dementia in Texas counties. A 2021 systematic review in Current Alzheimer Research synthesized 15 studies and concluded that low-dose lithium (microdose to 300mg lithium carbonate equivalent) demonstrated consistent inhibition of GSK-3β, a kinase implicated in tau hyperphosphorylation and amyloid precursor protein processing — both central pathological features of Alzheimer's disease.
Attia is explicit that the evidence for low-dose lithium as a longevity supplement is preliminary and largely epidemiological. He frames it as a low-risk, potentially high-reward intervention given its safety profile at doses far below psychiatric use. This is consistent with his broader framework: when downside risk is low and mechanistic rationale is strong, the bar for personal experimentation is different than the bar for a population-level clinical recommendation.
6. Aspirin and Other Pharmacological Considerations
While not supplements, it's worth noting that Attia publicly changed his position on low-dose aspirin for primary cardiovascular prevention after the ASPREE trial demonstrated that in adults over 70, aspirin increased all-cause mortality — driven primarily by an increase in cancer-related deaths that offset cardiovascular benefit (McNeil et al., NEJM 2018; PMID: 30221597). This reversal illustrates that his framework is genuinely responsive to evidence, not committed to any particular protocol.
---
Attia Rapamycin Protocol: The Most Controversial Element
No part of Peter Attia's approach generates more debate than rapamycin. Rapamycin (sirolimus) is an mTOR inhibitor originally developed as a transplant antirejection drug, and it is the only pharmacological intervention that has consistently extended lifespan in multiple mammalian species (Harrison et al., Nature 2009; PMID: 19587680).
mTOR (mechanistic target of rapamycin) is a master nutrient-sensing pathway. When mTOR is chronically activated — by excess amino acids, glucose, and growth signals — it suppresses autophagy, the cellular cleanup process that removes damaged organelles and misfolded proteins. Chronic mTOR activation is associated with accelerated aging, cancer, and metabolic disease. Rapamycin's effect is to periodically suppress mTOR signaling, allowing autophagy to proceed.
The Interventions Testing Program (ITP), a rigorous multi-site NIA-funded program, found that rapamycin extended median lifespan by 9–14% in genetically heterogeneous mice even when started at the equivalent of 60 human years — a finding unprecedented among pharmacological interventions in mammals (Harrison et al., Nature 2009; PMID: 19587680). Subsequent ITP studies found additive lifespan effects when rapamycin was combined with other interventions, though the mechanistic basis for these interactions remains under investigation.
What Attia Actually Does (and Doesn't Claim)
Attia is careful to frame rapamycin as an off-label experiment rather than a proven human longevity intervention. He uses it at a low, pulsed dose (typically 5–6 mg once per week) rather than the daily high-dose regimen used in transplant patients — the daily high-dose approach produces well-documented immunosuppression, impaired wound healing, dyslipidemia, and metabolic side effects that would be unacceptable for healthy people.
The pulsed-low-dose strategy is based on the pharmacokinetics of mTOR inhibition: a single weekly dose inhibits mTOR Complex 1 (mTORC1, which mediates autophagy benefits and is the primary target of rapamycin's longevity effects) without significantly suppressing mTOR Complex 2 (mTORC2, which manages immune function, glucose metabolism, and cytoskeletal organization). This mechanistic rationale is supported by the fact that mTORC2 is substantially less sensitive to rapamycin and requires chronic daily exposure to become inhibited — the kinetics of weekly dosing allow mTORC2 activity to recover between doses.
This theoretical basis is supported by animal pharmacokinetics but has not been validated in a large randomized human trial — which Attia consistently acknowledges. The PEARL trial, an ongoing placebo-controlled study of low-dose rapamycin in healthy older adults, is expected to provide the first systematic human data on biomarker and functional outcomes.
He has also noted that he monitors specific biomarkers while on rapamycin: fasting glucose, HbA1c, lipid panels, and immune markers, because individual responses vary considerably. He pauses rapamycin around periods of significant infection risk, surgery, or intensive training blocks where mTORC1 activity supports muscle protein synthesis.
Timing Rapamycin Around Resistance Training
One underappreciated tension in Attia's protocol is the relationship between mTOR suppression and muscle protein synthesis. mTORC1 is the primary driver of anabolic signaling after resistance exercise — it integrates leucine sensing, IGF-1 signaling, and mechanical load to trigger muscle hypertrophy. If rapamycin is dosed near a training session, it theoretically blunts this anabolic response.
For this reason, Attia structures his weekly rapamycin dose around training timing — taking it on a day that is maximally separated from his heaviest resistance training sessions. This is a level of protocol granularity that reflects genuine mechanistic reasoning, not supplement routine inertia.
Why This Matters for the Supplement World
Rapamycin is a prescription drug, not a supplement, and Ones does not include it in any formula. But the mechanistic logic — periodic mTOR suppression and autophagy enhancement — is relevant because several dietary and supplement strategies can achieve modest mTOR modulation without prescription drugs. These include:
- Time-restricted eating / intermittent fasting (reduces mTOR signaling during fasted states by lowering insulin and amino acid availability)
- Spermidine (found in wheat germ, aged cheese, and available as a supplement; induces autophagy through a distinct pathway involving inhibition of EP300 acetyltransferase, independent of mTOR)
- Resveratrol / pterostilbene (activates SIRT1 and has modest mTOR-inhibitory effects, though oral bioavailability of resveratrol is debated; pterostilbene has superior bioavailability)
- Berberine (activates AMPK, an upstream mTOR suppressor studied at 500mg 2–3x/day; also improves insulin sensitivity and has demonstrated LDL-lowering effects)
- Fisetin (a flavonoid with senolytic properties and mild mTOR-inhibitory effects, increasingly studied in aging research)
If rapamycin represents the aggressive end of the mTOR-suppression spectrum, these dietary and supplement strategies represent the conservative end — appropriate for most people without medical supervision, and potentially additive with fasting protocols.
---
Outlive Supplements: What the Book Actually Recommends
Attia's Outlive does not read as a supplement manual — the book is primarily about the four major chronic diseases (cardiovascular disease, cancer, neurodegenerative disease, and type 2 diabetes) and the behavioral foundations of longevity: exercise, sleep, nutrition, and emotional health. Supplements appear as supporting characters, not protagonists.
That said, the book's framework is essential context for understanding why Attia takes what he takes:
The Four Horsemen Framework: Attia organizes longevity medicine around the four leading causes of death and disability in aging adults. His supplement strategy is therefore calibrated to:
- Reduce cardiovascular risk (omega-3s, vitamin D, berberine for metabolic health, ApoB-lowering strategies)
- Reduce cancer risk (maintaining metabolic health, avoiding chronic hyperinsulinemia)
- Support cognitive healthspan (omega-3s, creatine, magnesium L-threonate, possibly lithium orotate)
- Preserve musculoskeletal function (creatine, protein, vitamin D, magnesium)
What He Has Stopped Taking: This is equally instructive. Attia has publicly stated he dropped high-dose vitamin C and NAC during periods of heavy exercise training, citing evidence that antioxidant supplementation can blunt mitochondrial biogenesis adaptations from exercise — a finding from Ristow et al. (Proceedings of the National Academy of Sciences 2009; PMID: 19433800) that showed supplemental vitamins C and E inhibited insulin sensitivity improvements and endurance adaptations in exercising humans. The mechanism is counterintuitive: reactive oxygen species (ROS) generated during exercise act as signaling molecules that activate PGC-1α, the master regulator of mitochondrial biogenesis. Exogenous antioxidants quench these ROS, blunting the adaptive signal. This level of nuance — removing a supplement that sounds healthy because it may impair a training adaptation — is what separates Attia's approach from most.
Sleep as the Foundation: Attia dedicates significant attention to sleep optimization, calling it the single most effective recovery and brain-maintenance tool available. While he is cautious about sleep supplements (he has been critical of melatonin as a primary sleep intervention, noting its effect is primarily chronobiotic rather than soporific), he discusses magnesium glycinate, apigenin, and low-dose phosphatidylserine as potential sleep supports that work through evidence-backed mechanisms without producing the rebound insomnia or tolerance associated with sedative agents.
Lipid Management: Attia is a strong proponent of treating ApoB as a primary cardiovascular risk marker rather than relying on LDL-C alone. For readers exploring the supplement side of lipid management, the evidence on what supplements affect ApoB is an important companion read to Attia's overall cardiovascular strategy. He views ApoB reduction as a priority second only to not smoking in terms of modifiable cardiovascular risk — and he is unambiguous that most supplements have only modest effects on ApoB compared to pharmacological interventions like statins or PCSK9 inhibitors, which is why metabolic health (insulin sensitivity, body composition, exercise) is the primary lever.
---
Attia Magnesium Creatine: The Pairing That Makes Practical Sense
While Attia doesn't necessarily market magnesium and creatine as a branded stack, they frequently appear together in his public discussions for overlapping mechanistic reasons. Understanding why these two work well together — and what the science actually says — is useful for anyone trying to build a longevity-oriented supplement protocol.
The Mechanistic Overlap: Both magnesium and creatine are centrally involved in ATP metabolism. Creatine functions as a phosphate buffer, rapidly regenerating ATP from ADP during high-demand states. Magnesium is essential for the enzymatic activity of creatine kinase — the enzyme that catalyzes this phosphate transfer. Additionally, the biologically active form of ATP is Mg-ATP, meaning that magnesium deficiency directly impairs the cellular energy currency that creatine is trying to replenish. The two are therefore not merely additive — magnesium is upstream of creatine's mechanism.
Creatine Uptake and Insulin Sensitivity: Creatine is transported into muscle cells via sodium-dependent creatine transporters (SLC6A8) in a process facilitated by insulin signaling. Magnesium deficiency is associated with insulin resistance, which may impair cellular creatine uptake and reduce the effectiveness of creatine supplementation. This suggests that correcting magnesium status before or alongside creatine loading is not just theoretically sound — it may improve creatine's functional response.
Sleep and Recovery Synergy: Attia frequently discusses the interconnection between sleep quality, recovery, and musculoskeletal health. Magnesium glycinate taken in the evening (200–400mg elemental) has demonstrated reductions in sleep onset latency and improvements in sleep efficiency in older adults with poor sleep (Abbasi et al., Journal of Research in Medical Sciences 2012; PMID: 23853635). Creatine taken in the morning supports daytime cognitive performance and anaerobic capacity during training. Together, they address two different but complementary windows of the recovery cycle.
Cognitive Performance Under Stress: Both nutrients also converge on cognitive function. Creatine's role in brain phosphocreatine availability and magnesium's role in NMDA receptor modulation and synaptic plasticity make them mechanistically complementary for maintaining cognitive performance under acute stress or sleep deprivation — a scenario Attia explicitly discusses in the context of modern work and travel demands.
For athletes and active individuals specifically, the interactions between these two nutrients and exercise performance are worth examining in depth — see our article on daily supplements for athletes and bioavailability for a broader performance context.
---
Beyond the Stack: What Attia's Framework Reveals About Personalized Supplementation
The most important lesson from Peter Attia's supplement approach is not which capsules he swallows — it's the decision architecture he uses. That architecture has five components that apply regardless of the specific ingredients:
1. Measure Before You Supplement
Attia does not guess at deficiency. He measures 25-OH vitamin D, Omega-3 Index, fasting glucose, HbA1c, ApoB, and a comprehensive metabolic panel before deciding what to add. This is the only way to distinguish a supplement that fills a real gap from one that creates excess — particularly relevant for fat-soluble vitamins like D and K, which accumulate.
2. Use Clinical Doses, Not Label Doses
Many supplement labels contain doses that are below those used in the studies that justify the health claim. Attia consistently references the actual clinical trial doses — 4g EPA for REDUCE-IT, 2,000–4,000 IU D3 for VITAL-level outcomes, 3–5g creatine for sarcopenia prevention. The gap between a typical label dose and a clinical trial dose can be 2–10x.
3. Reassess as Biomarkers Change
Attia's stack has evolved publicly over time — he has added, removed, and modified doses based on new data and his own lab results. This dynamic approach is fundamentally different from a "forever stack" mentality. What you need at 40 with suboptimal omega-3 index and low vitamin D is different from what you need at 55 after three years of optimization.
4. Separate Supplementation From Exercise Adaptation
The Ristow antioxidant finding is the clearest example of a supplement that is beneficial in one context (sedentary individuals with high oxidative stress burden) and potentially counterproductive in another (trained athletes seeking mitochondrial adaptation). Context determines appropriateness.
5. Accept Uncertainty at the Frontier
Rapamycin, low-dose lithium, spermidine — Attia is explicit that these are frontier interventions with insufficient human trial data. He frames them as personal experiments with favorable risk/benefit profiles, not recommendations for broad adoption. This intellectual honesty about the boundary between evidence and hypothesis is what makes his framework credible.
If you are interested in how to structure your own biomarker-driven supplement review, the article on personalized supplement plans, bioavailability, and lab-backed dosing covers the practical framework for building a stack from your own lab results rather than someone else's.
---
What This Means for Your Formula
The Attia framework — biomarker-first, mechanism-driven, dynamically updated — is exactly what Ones is built to operationalize. Rather than offering a fixed longevity stack, the platform analyzes your blood work, wearable data, and health history to identify where your specific gaps and risks lie, then builds a custom formula from a curated catalog of clinically validated ingredients.
Several ingredients that Attia consistently discusses overlap directly with what Ones includes:
- Omega-3 (EPA/DHA): Ones includes a clinical-dose EPA/DHA combination calibrated to Omega-3 Index data from your blood panel. Rather than defaulting to a fixed 1g dose, the formula targets the biomarker threshold (8%+ Omega-3 Index) that Attia and cardiovascular researchers identify as protective.
- Vitamin D3 + K2 (MK-7): Ones pairs D3 with MK-7 specifically — the long-chain menaquinone with superior half-life and vascular protection compared to MK-4 — at doses determined by your 25-OH vitamin D result. This mirrors Attia's emphasis on testing to target rather than dosing to a population average.
- Magnesium Complex: Ones includes a Magnesium Complex system blend that combines multiple forms to address both peripheral and CNS magnesium status — relevant to both the cardiovascular and cognitive dimensions of Attia's magnesium rationale.
For ingredients at the frontier of Attia's protocol — rapamycin, low-dose lithium, spermidine — Ones encourages working directly with a healthcare provider, as these require individualized medical supervision beyond what any supplement platform can responsibly provide.
---
Key Takeaways
- Peter Attia's supplement approach is biomarker-driven, not trend-driven. He measures deficiencies, doses to clinical thresholds, and removes supplements when evidence suggests harm — including antioxidants that blunt exercise adaptations.
- The core high-evidence stack includes omega-3s (targeting 8%+ Omega-3 Index), vitamin D3+K2, magnesium (multiple forms), and creatine monohydrate — all supported by multiple randomized controlled trials and mechanistic evidence relevant to aging.
- Rapamycin is Attia's most controversial tool: a prescription mTOR inhibitor used at pulsed low doses (5–6mg weekly) to activate autophagy without producing the immunosuppression of transplant-dose protocols. It is not a supplement, and human longevity trial data remain preliminary.
- Magnesium and creatine form a mechanistically coherent pair: magnesium is upstream of creatine kinase activity and cellular ATP utilization, making magnesium sufficiency a prerequisite for optimal creatine response.
- The Outlive framework prioritizes exercise, sleep, and metabolic health first — supplements are precision tools for identified gaps, not substitutes for behavioral foundations.
- Applying Attia's precision logic to your own body requires your own biomarkers: Omega-3 Index, 25-OH vitamin D, ApoB, fasting glucose, and HbA1c are the starting tests — dosing from population averages without testing is exactly what his framework argues against.
---
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any new supplement protocol, particularly interventions discussed in an off-label context.